7 research outputs found
DRYAD Database for South African Adolescent study
Age and sexual debut data was generated from questionnaires. Sexual transmitted infection was generated from the laboratory from the specimens provided by study participant
Prevalence of any human papillomavirus (HPV), multiple infections, single infection, HR-HPV, probable HR-HPV and LR-HPV.
<p>Prevalence of any human papillomavirus (HPV), multiple infections, single infection, HR-HPV, probable HR-HPV and LR-HPV.</p
The prevalence of human papillomavirus genotypes according to study site in adolescents and young adults.
<p>HR-HPV types included HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58 and -59; probably or possible HR-HPV types included HPV-26, -53, -66, -67, -68, -70, -73 and -82; and low-risk (LR) HPV types HPV-6, -11, -40, 42, -54, -55, -61, -62, -64, -69, -71, -72, -81, -83, -84, -89 (HPV-CP6108) and–IS39 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0190166#pone.0190166.ref022" target="_blank">22</a>].</p
Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and young women (multivariable analysis).
<p>Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and young women (multivariable analysis).</p
Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and young women (univariate analysis).
<p>Human papillomavirus prevalence and factors associated with human papillomavirus in adolescents and young women (univariate analysis).</p
Prevalence of human papillomavirus (HPV) types targeted by current vaccines and non-vaccine types.
<p>Bivalent types: one or both HPV types targeted by the Cervarix HPV vaccine (HPV16/18); Quadrivalent types: one or more HPV types targeted by the Gardasil HPV vaccine (HPV6/11/16/18); Nonavalent types: one or more HPV types targeted by the Gardasil-9 HPV vaccine (HPV6/11/16/18/31/33/45/52/58); HR-HPV excluding vaccine & cross protective types (HPV-35/39/56/59).</p
Additional file 2 of Lactic acid from vaginal microbiota enhances cervicovaginal epithelial barrier integrity by promoting tight junction protein expression
Additional file 2: Supplementary Table 1. Proteins with significantly different abundance in women with high as compared to low L-LDH and D-LDH abundance*. Supplementary Table 2. Barrier-related proteins with significantly different abundance in women with high as compared to low L-LDH abundance*. Supplementary Table 3. Genes differentially expressed by L-LA, D-LA and HCL treatment of Ect cells*. Supplementary Table 4. Gene ontology pathways significantly enriched by L-LA and D-LA treatment of Ect cells. Supplementary Table 5. Tight junction genes differentially expressed by L-LA, D-LA and HCL treatment of Ect cells*. Supplementary Table 6. Tight junction genes differentially expressed by treatment of VK2 cells with bacterial culture supernatants*